Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
biotech · Acute Myeloid Leukemia (AML) · Ovarian Cancer · STRO
SUTRO BIOPHARMA
SUTRO BIOPHARMA, INC.
SUTRO BIOPHARMA drug portfolio — 21 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
2003 Founded
212 Employees
Public company Type
STRO · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2003
- Employees
- 212
- Programs
- 10
- Drugs
- 21
- Patents
- 34
SUTRO BIOPHARMA pipeline
Portfolio lens on 21 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SUTRO BIOPHARMA drug portfolio — 21 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
US regulatory status: approved.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in SUTRO BIOPHARMA's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
Development asset linked to SUTRO BIOPHARMA in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor